Option chain shows key data for Regulus Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Regulus Therapeutics.

Regulus Therapeutics (NASDAQ:RGLS) Stock, Option Chain

Regulus Therapeutics

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Medical,Research,Laboratory:,Portrait,Of,A,Handsome,Male,Scientist,Using

Biotech

News

Health Care

Movers

Trading Ideas

General

RGLS

Regulus Therapeutics&#39; Phase 1b study shows farabursen 300 mg slowed kidney volume growth in ADPKD patients with a favorable safety profile.

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease

Image26

Price Target

Markets

Analyst Ratings

BALL

BIRK

CHRW

CPRI

CRDO

ETSY

GTHX

Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday

document-428338_1280

Regulus Therapeutics announced positive results from its study related to the treatment of autosomal dominant polycystic kidney disease (AKPD).

What&#39;s Going On With Regulus Therapeutics Stock Monday?

Regulus Therapeutics Inc

REGULUS RES INC by Regulus Resources, Inc.

Regulus Resources Inc

Press Releases

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Earnings

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Anika Therapeutics

Annexon

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cardiff Oncology

Cargo Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Genfit

Gossamer Bio

TuHURA Biosciences

Inhibrx Biosciences

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Korro Bio

Ocugen

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tevogen Bio Holdings

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Y-mAbs Therapeutics

Wells Fargo

Canaccord Genuity

HC Wainwright & Co.

Oppenheimer

Jones Trading

Comments

Regulus Therapeutics

Regulus Therapeutics (RGLS) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell